BackBioline Rx Overview

Bioline Rx Intangible Assets

Bioline Rx's intangible assets is $16M.

Get informed when a big investor buys or sells

+ Follow
Intangible Assets
$16.33M

Peer trimmed avg / median

Loading

Bioline Rx Intangible Assets History

Loading

Bioline Rx vs. peers: Intangible Assets Comparison

Loading

Bioline Rx Intangible Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Bioline Rx (BLRX) FAQ

Bioline Rx (BLRX) currently reports a intangible assets of $16M as of June 2026. In the prior-year period, the figure was $0. Use the charts on this page to explore Bioline Rx's intangible assets history and peer comparisons.

Bioline Rx's intangible assets changed from $0 to $16M (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Bioline Rx reported $16M in intangible assets as of June 2026. In the prior-year period, the figure was $0. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current intangible assets of $16M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Bioline Rx, and consider following BLRX for alerts when major investors trade the stock.

Bioline Rx is classified in the Healthcare sector. On intangible assets, it currently shows $16M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BLRX with unrelated industries.